Patrick Gee
Overview
Explore the profile of Patrick Gee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kome A, Yang A, Gee P, Klein K
Diabetes Ther
. 2025 Mar;
PMID: 40032808
People living with type 2 diabetes mellitus (T2DM) are at risk of developing diabetes-related complications such as chronic kidney disease (CKD). Screening for CKD is considered the standard of diabetes...
2.
Iltis A, Roberts G, Moxey-Mims M, Conell A, Davis J, Gbadegesin R, et al.
J Am Soc Nephrol
. 2024 Dec;
PMID: 39724023
No abstract available.
3.
Johannes C, Ziemiecki R, Pladevall-Vila M, Ebert N, Kovesdy C, Thomsen R, et al.
Diabetes Ther
. 2024 Dec;
16(2):205-226.
PMID: 39688776
Introduction: The clinical landscape for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is rapidly evolving. As part of the FOUNTAIN platform (NCT05526157; EUPAS48148),...
4.
Russmann D, Roy-Chaudhury P, Chertow G, Gee P, Chauhan C, Macari S, et al.
Clin J Am Soc Nephrol
. 2024 Aug;
19(11):1496-1498.
PMID: 39213129
No abstract available.
5.
Ajayi O, Gee P, Mulhall H, Richards D, Riggare S
BMJ
. 2024 Jun;
385:q1411.
PMID: 38942435
No abstract available.
6.
Forfang D, Crabtree B, Gee P, Solomon J, Bologna P, Nelson T, et al.
Clin J Am Soc Nephrol
. 2023 Apr;
18(6):689-690.
PMID: 37071607
No abstract available.
7.
Nicholas S, Wright E, Billings L, Ambriz E, Gee P, Peeler T
Adv Ther
. 2022 Oct;
40(1):1-18.
PMID: 36282450
Comorbid type 2 diabetes mellitus (T2D) and chronic kidney disease (CKD) is associated with poor health outcomes and a high economic burden. Management of these conditions remains a significant challenge...
8.
Li S, Vandvik P, Lytvyn L, Guyatt G, Palmer S, Rodriguez-Gutierrez R, et al.
BMJ
. 2021 May;
373:n1091.
PMID: 33975892
Clinical Question: What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual care (lifestyle interventions and/or other...
9.
Lamontagne F, Stegemann M, Agarwal A, Agoritsas T, Siemieniuk R, Rochwerg B, et al.
BMJ
. 2021 Mar;
372:n526.
PMID: 33649077
Clinical Question: What is the role of drugs in preventing covid-19? WHY DOES THIS MATTER?: There is widespread interest in whether drug interventions can be used for the prevention of...
10.
Agarwal A, Hunt B, Stegemann M, Rochwerg B, Lamontagne F, Ac Siemieniuk R, et al.
BMJ
. 2020 Sep;
370:m3379.
PMID: 32887691
Updates: This is the fourteenth version (thirteenth update) of the living guideline, replacing earlier versions (available as data supplements). New recommendations will be published as updates to this guideline. Clinical...